Get the Stockscreener App
1.98
0.51%
0.01
After Hours:
1.99
0.01
+0.51%
Tscan Therapeutics Inc stock is traded at $1.98, with a volume of 697.32K.
It is up +0.51% in the last 24 hours and up +5.32% over the past month.
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.
See More
Previous Close:
$1.97
Open:
$1.96
24h Volume:
697.32K
Relative Volume:
2.12
Market Cap:
$103.89M
Revenue:
$21.05M
Net Income/Loss:
$-89.22M
P/E Ratio:
-1.1061
EPS:
-1.79
Net Cash Flow:
$-64.50M
1W Performance:
-5.26%
1M Performance:
+5.32%
6M Performance:
+67.80%
1Y Performance:
-64.58%
1-Day Range:
$1.93
$2.03
1-Week Range:
$1.90
$2.30
52-Week Range:
$1.02
$6.225
Tscan Therapeutics Inc Stock (TCRX) Company Profile
Name
Tscan Therapeutics Inc
Sector
Industry
Phone
857-399-9500
Address
830 WINTER STREET, WALTHAM
Compare TCRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TCRX
Tscan Therapeutics Inc
|
1.98 | 111.79M | 21.05M | -89.22M | -64.50M | -1.79 |
|
VRTX
Vertex Pharmaceuticals Inc
|
421.15 | 105.19B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
450.68 | 60.24B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.86 | 61.82B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
798.94 | 49.09B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
351.09 | 37.52B | 4.56B | -176.77M | 225.30M | -1.7177 |
Tscan Therapeutics Inc Stock (TCRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-16-24 | Initiated | BTIG Research | Buy |
| May-13-24 | Initiated | Needham | Buy |
| Jun-22-23 | Initiated | Wedbush | Outperform |
Tscan Therapeutics Inc Stock (TCRX) Latest News
How to forecast TScan Therapeutics Inc. trends using time seriesWall Street Watch & Long-Term Capital Growth Strategies - newser.com
Short interest data insights for TScan Therapeutics Inc.2025 Macro Impact & Low Drawdown Investment Strategies - newser.com
TScan Therapeutics Inc. stock daily chart insightsJuly 2025 Intraday Action & Capital Efficient Trading Techniques - newser.com
Will TScan Therapeutics Inc. stock maintain momentum in 2025Portfolio Profit Report & AI Based Buy/Sell Signal Reports - newser.com
Will TScan Therapeutics Inc. stock continue dividend increasesWeekly Profit Recap & Free Long-Term Investment Growth Plans - newser.com
What the charts say about TScan Therapeutics Inc. today2025 Winners & Losers & AI Driven Stock Reports - newser.com
Is TScan Therapeutics Inc a good long term investmentSwing Trading Ideas & Fast Growing Capital Growth - earlytimes.in
Goldman Sachs Group Inc. Buys 9,676 Shares of TScan Therapeutics, Inc. $TCRX - Defense World
H.C. Wainwright Maintains TScan Therapeutics(TCRX.US) With Buy Rating, Maintains Target Price $10 - 富途牛牛
Risk adjusted return profile for TScan Therapeutics Inc. analyzedTrade Performance Summary & Growth Focused Entry Point Reports - newser.com
TScan Therapeutics, Inc. (NASDAQ:TCRX) Receives Consensus Rating of “Buy” from Analysts - Defense World
Brokerages Set TScan Therapeutics, Inc. (NASDAQ:TCRX) PT at $7.80 - MarketBeat
How to build a custom watchlist for TScan Therapeutics Inc.July 2025 Opening Moves & Advanced Technical Signal Analysis - newser.com
Energy Moves: Will TScan Therapeutics Inc benefit from seasonalityDip Buying & Fast Entry Momentum Trade Alerts - خودرو بانک
Tscan Therapeutics Inc Stock (TCRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Tscan Therapeutics Inc Stock (TCRX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Lynx1 Capital Management LP | 10% Owner |
May 20 '25 |
Buy |
1.20 |
1,200,000 |
1,440,000 |
7,946,141 |
| Lynx1 Capital Management LP | 10% Owner |
Dec 13 '24 |
Buy |
2.90 |
100,000 |
290,140 |
5,357,347 |
| Lynx1 Capital Management LP | 10% Owner |
Dec 12 '24 |
Buy |
3.01 |
31,800 |
95,629 |
5,257,347 |
| Lynx1 Capital Management LP | 10% Owner |
Nov 15 '24 |
Buy |
4.34 |
947 |
4,114 |
5,225,547 |
2.05%
4.71%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):